FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1567944093> ?p ?o ?g. }

• W1567944093 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CABackground:Lymphomas are still incurable in many patients and novel active compounds are actively being sought. We previously reported single agent activity of the BET bromodomain OTX015 in lymphoma cell lines and in vivo (AACR 2012; ICML 2013). Here, we report a study of the mechanism of action of OTX015 and its activity in combination with other anti-cancer compounds.Methods:Cell lines: 22 diffuse large B-cell lymphoma (DLBCL), 4 mantle cell lymphomas, 3 multiple myelomas, 3 splenic marginal zone lymphoma and 1 prolymphocytic leukemia. Anti-proliferative of OTX015 (OncoEthix SA, Switzerland) was assessed by MTT and its cytotoxic activity by Annexin V staining and gene expression profiling (GEP) with Illumina HumanHT-12 Expression BeadChips. Data mining was done with LIMMA, GSEA, Metacore. Synergy was assessed in cells (2-5 cell lines) exposed for 72 h to increasing doses of OTX015 alone or in combination with increasing doses of other agents. MTT assays were performed and Chou-Talalay combination index (CI) calculated.Results:OTX015 (500 nM, 72h) showed cytostatic activity in 29/33 (88%) cell lines and apoptosis in 3/22 (14%). Mutations in genes coding for MYD88 and components of BCR (P=0.027), and ABC signaling phenotypes (P=0.008) were significantly associated with apoptosis induction. We performed GEP on 2 cell lines (SU-DHL-6, SU-DHL-2), treated with DMSO or OTX015 (500 nM) for 1, 2, 4, 8 or 12 hours. Most upregulated genes were histones. MYC target genes were highly significantly enriched among all OTX015 regulated transcripts and MYC was the most frequently downregulated gene. OTX015 also downregulated MYD88, IRAK1, TLR6, IL6, STAT3, and TNFRSF17, members of the NFKB, TLR and JAK/STAT pathways. NFKB target genes (IRF4, TNFAIP3 and BIRC3) were also downregulated (PCR). Immunoblotting and immunohistochemistry showed a reduction of transcriptionally active pSTAT3 in 2 ABC cell lines, and a reduction in nuclear localization of p50 (NFKB1), indicating an inhibitory effect of OTX015 on the canonical NFKB pathway. Finally, IL10 and IL4 production was reduced after 24 hours OTX015 treatment.Synergy was observed with everolimus (median CI=0.1; range 0.1-0.2), ibrutinib in ABC-DLBCL (CI=0.04; 0.02-0.1), idelalisib (CAL101) (CI=0.5; 0.04-2.4), vorinostat (CI=0.5; 0.3-0.6), rituximab (CI=0.5; 0.4-0.5), decitabine (CI=0.6; 0.6-0.7), lenalidomide (CI=0.7; 0.6-0.7), and all-trans retinoic acid (CI=0.4; .1-1.6). Additive effects were observed for combinations with romidepsin (CI=1.08; 1-1.22), bendamustine (CI=0.92; 0.83-1.1), and doxorubicin (CI=0.83; 0.71-0.96).Conclusions:OTX015 is a promising candidate for targeted combination therapies. A phase I study ([NCT01713582][1]) in patients with hematological neoplasias is underway and together with our preclinical data, may support further clinical investigations.Citation Format: Eugenio Gaudio, Elena Bernasconi, Ivo Kwee, Michela Boi, Paola Bonetti, Chiara Tarantelli, Andrea Rinaldi, Monica Testoni, Maurilio Ponzoni, Anastasios Stathis, Georg Stussi, Eugenia Riveiro, Patrice Herait, Emanuele Zucca, Francesco Bertoni. The BET Bromodomain inhibitor OTX015 targets the NFKB, TLR and JAK/STAT pathways and shows pre-clinical activity as single agent and in combination in mature B-cell tumors. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 5528. doi:10.1158/1538-7445.AM2014-5528 [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01713582&atom=%2Fcanres%2F74%2F19_Supplement%2F5528.atom" @default.
• W1567944093 created "2016-06-24" @default.
• W1567944093 creator A5006004932 @default.
• W1567944093 creator A5009234092 @default.
• W1567944093 creator A5011622095 @default.
• W1567944093 creator A5016760892 @default.
• W1567944093 creator A5021627015 @default.
• W1567944093 creator A5026796330 @default.
• W1567944093 creator A5036266208 @default.
• W1567944093 creator A5039188583 @default.
• W1567944093 creator A5048622832 @default.
• W1567944093 creator A5054086723 @default.
• W1567944093 creator A5059963876 @default.
• W1567944093 creator A5064713685 @default.
• W1567944093 creator A5066518317 @default.
• W1567944093 creator A5073467962 @default.
• W1567944093 creator A5079771818 @default.
• W1567944093 date "2014-09-30" @default.
• W1567944093 modified "2023-09-26" @default.
• W1567944093 title "Abstract 5528: The BET Bromodomain inhibitor OTX015 targets the NFKB, TLR and JAK/STAT pathways and shows pre-clinical activity as single agent and in combination in mature B-cell tumors" @default.
• W1567944093 doi "https://doi.org/10.1158/1538-7445.am2014-5528" @default.
• W1567944093 hasPublicationYear "2014" @default.
• W1567944093 type Work @default.
• W1567944093 sameAs 1567944093 @default.
• W1567944093 citedByCount "0" @default.
• W1567944093 crossrefType "proceedings-article" @default.
• W1567944093 hasAuthorship W1567944093A5006004932 @default.
• W1567944093 hasAuthorship W1567944093A5009234092 @default.
• W1567944093 hasAuthorship W1567944093A5011622095 @default.
• W1567944093 hasAuthorship W1567944093A5016760892 @default.
• W1567944093 hasAuthorship W1567944093A5021627015 @default.
• W1567944093 hasAuthorship W1567944093A5026796330 @default.
• W1567944093 hasAuthorship W1567944093A5036266208 @default.
• W1567944093 hasAuthorship W1567944093A5039188583 @default.
• W1567944093 hasAuthorship W1567944093A5048622832 @default.
• W1567944093 hasAuthorship W1567944093A5054086723 @default.
• W1567944093 hasAuthorship W1567944093A5059963876 @default.
• W1567944093 hasAuthorship W1567944093A5064713685 @default.
• W1567944093 hasAuthorship W1567944093A5066518317 @default.
• W1567944093 hasAuthorship W1567944093A5073467962 @default.
• W1567944093 hasAuthorship W1567944093A5079771818 @default.
• W1567944093 hasConcept C104317684 @default.
• W1567944093 hasConcept C121608353 @default.
• W1567944093 hasConcept C126322002 @default.
• W1567944093 hasConcept C190283241 @default.
• W1567944093 hasConcept C203014093 @default.
• W1567944093 hasConcept C2778305200 @default.
• W1567944093 hasConcept C2778923194 @default.
• W1567944093 hasConcept C2779338263 @default.
• W1567944093 hasConcept C2780862049 @default.
• W1567944093 hasConcept C2781462825 @default.
• W1567944093 hasConcept C41091548 @default.
• W1567944093 hasConcept C502942594 @default.
• W1567944093 hasConcept C54355233 @default.
• W1567944093 hasConcept C64927066 @default.
• W1567944093 hasConcept C71924100 @default.
• W1567944093 hasConcept C74401373 @default.
• W1567944093 hasConcept C86803240 @default.
• W1567944093 hasConceptScore W1567944093C104317684 @default.
• W1567944093 hasConceptScore W1567944093C121608353 @default.
• W1567944093 hasConceptScore W1567944093C126322002 @default.
• W1567944093 hasConceptScore W1567944093C190283241 @default.
• W1567944093 hasConceptScore W1567944093C203014093 @default.
• W1567944093 hasConceptScore W1567944093C2778305200 @default.
• W1567944093 hasConceptScore W1567944093C2778923194 @default.
• W1567944093 hasConceptScore W1567944093C2779338263 @default.
• W1567944093 hasConceptScore W1567944093C2780862049 @default.
• W1567944093 hasConceptScore W1567944093C2781462825 @default.
• W1567944093 hasConceptScore W1567944093C41091548 @default.
• W1567944093 hasConceptScore W1567944093C502942594 @default.
• W1567944093 hasConceptScore W1567944093C54355233 @default.
• W1567944093 hasConceptScore W1567944093C64927066 @default.
• W1567944093 hasConceptScore W1567944093C71924100 @default.
• W1567944093 hasConceptScore W1567944093C74401373 @default.
• W1567944093 hasConceptScore W1567944093C86803240 @default.
• W1567944093 hasLocation W15679440931 @default.
• W1567944093 hasOpenAccess W1567944093 @default.
• W1567944093 hasPrimaryLocation W15679440931 @default.
• W1567944093 hasRelatedWork W1493712898 @default.
• W1567944093 hasRelatedWork W1611172254 @default.
• W1567944093 hasRelatedWork W1984720955 @default.
• W1567944093 hasRelatedWork W1984941008 @default.
• W1567944093 hasRelatedWork W2008045139 @default.
• W1567944093 hasRelatedWork W2014608290 @default.
• W1567944093 hasRelatedWork W2029449207 @default.
• W1567944093 hasRelatedWork W2070162304 @default.
• W1567944093 hasRelatedWork W2253637476 @default.
• W1567944093 hasRelatedWork W2343751321 @default.
• W1567944093 hasRelatedWork W2499852336 @default.
• W1567944093 hasRelatedWork W2502959994 @default.
• W1567944093 hasRelatedWork W2548435760 @default.
• W1567944093 hasRelatedWork W2564630480 @default.
• W1567944093 hasRelatedWork W2606328154 @default.
• W1567944093 hasRelatedWork W2741792295 @default.
• W1567944093 hasRelatedWork W2887424089 @default.
• W1567944093 hasRelatedWork W2979312664 @default.
• W1567944093 hasRelatedWork W3081556464 @default.
• W1567944093 hasRelatedWork W3109760887 @default.
• W1567944093 isParatext "false" @default.
• W1567944093 isRetracted "false" @default.

• next